Cargando…
Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia
Real-world evidence of the vaccine effectiveness (VE) of different COVID-19 vaccines is needed in order to better shape vaccine recommendations and policies and increase vaccine acceptance, especially among vulnerable populations such as the elderly. We analyzed the early effectiveness of four COVID...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954033/ https://www.ncbi.nlm.nih.gov/pubmed/35335021 http://dx.doi.org/10.3390/vaccines10030389 |
_version_ | 1784675994187071488 |
---|---|
author | Petrović, Vladimir Vuković, Vladimir Marković, Miloš Ristić, Mioljub |
author_facet | Petrović, Vladimir Vuković, Vladimir Marković, Miloš Ristić, Mioljub |
author_sort | Petrović, Vladimir |
collection | PubMed |
description | Real-world evidence of the vaccine effectiveness (VE) of different COVID-19 vaccines is needed in order to better shape vaccine recommendations and policies and increase vaccine acceptance, especially among vulnerable populations such as the elderly. We analyzed the early effectiveness of four COVID-19 vaccines, namely BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 in population aged ≥60 years for symptomatic, mild and severe COVID-19, in the period January–April 2021 in Vojvodina, a northern province of Serbia. Incidence rates of SARS-CoV-2 infection were calculated using data from the provincial COVID-19 surveillance registry, and vaccination coverage data were obtained from the nationwide registry of administered COVID-19 vaccines. During the observation period, 134,535 subjects aged ≥60 years were fully vaccinated, of whom 87.7% received BBIBP-CorV, 7.1% BNT162b2 and 5.2% Gam-COVID-Vac vaccines. The estimated VE in fully vaccinated persons was 86.9% (95% CI, 86–87.7) for BBIBP-CorV, 95% (95% CI, 92.4–96.7) for Gam-COVID-Vac and 99% (95% CI, 97.8–99.5) for BNT162b2, while VE after the first dose of ChAdOx1 nCoV-19 was 88.6% (95% CI, 80.5–93.4). Estimates were similar when stratifying the analyses to severe and mild SARS-CoV-2 infections. Our analysis provides evidence of high early effectiveness of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 in elderly people in preventing symptomatic, severe and mild COVID-19 disease, particularly after being fully vaccinated. |
format | Online Article Text |
id | pubmed-8954033 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89540332022-03-26 Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia Petrović, Vladimir Vuković, Vladimir Marković, Miloš Ristić, Mioljub Vaccines (Basel) Communication Real-world evidence of the vaccine effectiveness (VE) of different COVID-19 vaccines is needed in order to better shape vaccine recommendations and policies and increase vaccine acceptance, especially among vulnerable populations such as the elderly. We analyzed the early effectiveness of four COVID-19 vaccines, namely BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 in population aged ≥60 years for symptomatic, mild and severe COVID-19, in the period January–April 2021 in Vojvodina, a northern province of Serbia. Incidence rates of SARS-CoV-2 infection were calculated using data from the provincial COVID-19 surveillance registry, and vaccination coverage data were obtained from the nationwide registry of administered COVID-19 vaccines. During the observation period, 134,535 subjects aged ≥60 years were fully vaccinated, of whom 87.7% received BBIBP-CorV, 7.1% BNT162b2 and 5.2% Gam-COVID-Vac vaccines. The estimated VE in fully vaccinated persons was 86.9% (95% CI, 86–87.7) for BBIBP-CorV, 95% (95% CI, 92.4–96.7) for Gam-COVID-Vac and 99% (95% CI, 97.8–99.5) for BNT162b2, while VE after the first dose of ChAdOx1 nCoV-19 was 88.6% (95% CI, 80.5–93.4). Estimates were similar when stratifying the analyses to severe and mild SARS-CoV-2 infections. Our analysis provides evidence of high early effectiveness of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 in elderly people in preventing symptomatic, severe and mild COVID-19 disease, particularly after being fully vaccinated. MDPI 2022-03-03 /pmc/articles/PMC8954033/ /pubmed/35335021 http://dx.doi.org/10.3390/vaccines10030389 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Petrović, Vladimir Vuković, Vladimir Marković, Miloš Ristić, Mioljub Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia |
title | Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia |
title_full | Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia |
title_fullStr | Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia |
title_full_unstemmed | Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia |
title_short | Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia |
title_sort | early effectiveness of four sars-cov-2 vaccines in preventing covid-19 among adults aged ≥60 years in vojvodina, serbia |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954033/ https://www.ncbi.nlm.nih.gov/pubmed/35335021 http://dx.doi.org/10.3390/vaccines10030389 |
work_keys_str_mv | AT petrovicvladimir earlyeffectivenessoffoursarscov2vaccinesinpreventingcovid19amongadultsaged60yearsinvojvodinaserbia AT vukovicvladimir earlyeffectivenessoffoursarscov2vaccinesinpreventingcovid19amongadultsaged60yearsinvojvodinaserbia AT markovicmilos earlyeffectivenessoffoursarscov2vaccinesinpreventingcovid19amongadultsaged60yearsinvojvodinaserbia AT risticmioljub earlyeffectivenessoffoursarscov2vaccinesinpreventingcovid19amongadultsaged60yearsinvojvodinaserbia |